Bio-Path Holdings, Inc. (NASDAQ:BPTH) Sees Significant Increase in Short Interest

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 388,600 shares, a growth of 3,947.9% from the September 30th total of 9,600 shares. Based on an average daily volume of 1,390,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 10.5% of the shares of the company are short sold.

Bio-Path Stock Up 0.9 %

BPTH stock traded up $0.01 during trading on Friday, hitting $1.08. 61,303 shares of the company traded hands, compared to its average volume of 1,213,142. Bio-Path has a 1 year low of $0.85 and a 1 year high of $14.42. The stock’s 50-day simple moving average is $1.05 and its 200 day simple moving average is $1.84.

Bio-Path (NASDAQ:BPTH) last posted its earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.54) by $0.38. During the same quarter last year, the firm earned ($10.60) earnings per share. As a group, sell-side analysts expect that Bio-Path will post -6.2 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. StockNews.com began coverage on shares of Bio-Path in a research report on Wednesday. They set a “sell” rating for the company. Roth Mkm reaffirmed a “buy” rating and issued a $20.00 price target on shares of Bio-Path in a report on Monday, July 8th.

Institutional Investors Weigh In On Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC purchased a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent quarter. 5.74% of the stock is currently owned by hedge funds and other institutional investors.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.